ReviewCytotherapy2016
T-cell therapies for HIV: Preclinical successes and current clinical strategies.
Review in Cytotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 38 citations in OpenAlex.
- NK cell immunotherapy after analytic treatment interruption is associated with HIV viral control.Molecular therapy. Advances · 2026Article
- Product Nkabinde Mediates Cytokine Modulation and Antiviral Activity in HIV-Infected MT4 Cells.International journal of molecular sciences · 2026Article
- Multiplex engineering of rhesus macaque NK cells enhances homing to sites of HIV replication in B cell follicles.bioRxiv : the preprint server for biology · 2026Article
- NK cell immunotherapy administered at the time of HIV recrudescence is associated with viral control.bioRxiv : the preprint server for biology · 2025Article
- Cell Granularity Reflects Immune Cell Function and Enables Selection of Lymphocytes with Superior Attributes for Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIVFrontiers in immunology · 2022Article
- T cell receptor-targeted immunotherapeutics drive selective in vivo HIV- and CMV-specific T cell expansion in humanized mice.The Journal of clinical investigation · 2021Article
- A participant-derived xenograft model of HIV enables long-term evaluation of autologous immunotherapies.The Journal of experimental medicine · 2021Article
- Engineered Antigen-Specific T Cells Secreting Broadly Neutralizing Antibodies: Combining Innate and Adaptive Immune Response against HIV.Molecular therapy. Methods & clinical development · 2020Article
- Scaffold-Mediated Static Transduction of T Cells for CAR-T Cell Therapy.Advanced healthcare materials · 2020Article
- Preclinical Development and Clinical-Scale Manufacturing of HIV Gag-Specific, LentivirusModified CD4 T Cells for HIV Functional Cure.Molecular therapy. Methods & clinical development · 2020Article
- Virus-specific T cells for malignancies - then, now and where to?Current stem cell reports · 2020Article
- Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype.Journal of visualized experiments : JoVE · 2020Article
- Rapid Transduction and Expansion of Transduced T Cells with Maintenance of Central Memory Populations.Molecular therapy. Methods & clinical development · 2020Article
- A Trispecific Anti-HIV Chimeric Antigen Receptor Containing the CCR5 N-Terminal Region.Frontiers in cellular and infection microbiology · 2020Article
- Nanoparticle-Based Immunoengineered Approaches for Combating HIV.Frontiers in immunology · 2020Review
- Review: HIV-1 phylogeny during suppressive antiretroviral therapy.Current opinion in HIV and AIDS · 2019Review
- Microglial Cells: The Main HIV-1 Reservoir in the Brain.Frontiers in cellular and infection microbiology · 2019Review
- Chimeric antigen receptor T-cell approaches to HIV cure.Current opinion in HIV and AIDS · 2018Review
- Therapeutic Targeting of HIV Reservoirs: How to Give T Cells a New Direction.Frontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Although antiretroviral therapy (ART) has been successful in controlling HIV infection, it does not provide a permanent cure, requires lifelong treatment, and HIV-positive individuals are left with social concerns such as stigma. The recent application of T cells to treat cancer and viral reactivations post-transplant offers a potential strategy to control HIV infection. It is known that naturally occurring HIV-specific T cells can inhibit HIV initially, but this response is not sustained in the majority of people living with HIV. Genetically modifying T cells to target HIV, resist infection, and persist in the immunosuppressive environment found in chronically infected HIV-positive individuals might provide a therapeutic solution for HIV. This review focuses on successful preclinical studies and current clinical strategies using T-cell therapy to control HIV infection and mediate a functional cure solution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.